Quantcast

Latest Uric acid Stories

2010-11-09 06:00:00

SAN DIEGO, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the three and nine months ended September 30, 2010. "Recent data from two clinical studies demonstrate that the combination of RDEA594 with either of the currently marketed drugs for gout, febuxostat...

2010-11-08 06:00:00

SAN DIEGO, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol. RDEA594, Ardea's lead product candidate for the chronic management of hyperuricemia and gout, is an orally administered compound that inhibits the URAT1 transporter, a biological mechanism that...

2010-11-05 07:00:00

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced a free Sermo Report titled, "Treatment Options for Gout". The report gathered feedback from physicians to better understand how they currently treat gout and if they would consider using new treatments. While many physicians who participated felt that current gout treatments effectively manage acute and suppressed gout flares, 63% confirmed...

2010-10-14 07:00:00

EXTON, Pa., Oct. 14 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the recent release of a syndicated report focused on the management and treatment of gout in the US. ChartTrends®: Gout is an annual publication based on patient and laboratory data collected from over 1,000 gout patient charts. It provides insight into the factors that drive decisions to treat, brand selection of uric acid lowering (UAL) therapies, patient characterizations and...

2010-09-14 17:09:00

EAST BRUNSWICK, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and...

2010-09-14 16:52:00

SILVER SPRING, Md., Sept. 14 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Gout occurs due to an excess of the bodily waste uric acid, which is eventually deposited as needle-like crystals...

2010-09-13 16:05:00

ATLANTA and DEERFIELD, Ill., Sept. 13 /PRNewswire/ -- The Arthritis Foundation and Takeda Pharmaceuticals North America, Inc., today announced the launch of a new educational campaign, Gout Living, to help increase understanding and encourage better management of gout. The campaign, which includes the first-ever gout public service announcements (PSAs), aims to encourage those living with the disease to be proactive about their health. The PSAs, which will be available via television, radio...

2010-06-18 07:00:00

ROME, June 18 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by...

2010-06-11 13:40:14

Allopurinol helps kidney function and cuts heart risks A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a...

2010-06-10 08:00:00

WASHINGTON, June 10 /PRNewswire/ -- The 2010 Gout Attitudes Patient Survey (GAPS), a new study of Americans with gout, released today by Men's Health Network (MHN), sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.